Compare Gap Inc (GAP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Mesoblast Limited — how do they compare? Gap Inc trades at $20.9 (market cap $7.74B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Gap Inc is far larger — about 3.6× Mesoblast Limited's market cap, and Gap Inc pays a 3.25% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GAP | MESO | |
|---|---|---|
Market Cap | $7.74B | $2.16B |
Sector | Consumer Cyclical | Technology |
52-Week High | $29.13 | $20.96 |
52-Week Low | $18.35 | $12.88 |
Enterprise Value | $10.82B | $2.17B |
Dividend Yield | 3.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $20.47, down 0.24% on the day, with a bullish technical signal supported by strong momentum indicators. The stock shows attractive valuation metrics, including a P/E of 8.12 and P/S of 0.51, while recent earnings have generally beaten expectations. Operating cash flow remains robust at $1.49 billion for 2025, and the company continues its digital transformation with AI initiatives.
The outlook is positive with a consensus price target of $26.64, implying 30% upside. Risks include competitive pressures and ongoing investigations by Pomerantz Law Firm. Analyst sentiment is mixed but leans bullish, with 39.58% recommending buy. The stock presents a value opportunity if turnaround efforts sustain momentum.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
